Björn Dahlöf

Department of Molecular and Clinical

Medicine

Mail

bjorn.dahlof@gu.se

Visiting address

Medicinkliniken

Göteborg

Postal address

Su sahlgrenska

41345 Göteborg

Publications

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension
phase

A. Gupta, D. Thompson, A. Whitehouse, T. Collier, Björn Dahlöf, N. Poulter, R. Collins, P. Sever, Ascot Investigators Ascot Investigators
Lancet - 2017-01-01
Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27
RCTs.

Mats Börjesson, Aron Onerup, Stefan Lundqvist, Björn Dahlöf
British journal of sports medicine - 2016-01-01
Hypertoni

Mats Börjesson, Aron Onerup, Stefan Lundqvist, Björn Dahlöf
FYSS - 2016-01-01
Aerob fysisk aktivitet sänker blodtrycket vid
hypertoni.

Mats Börjesson, Aron Onerup, Stefan Lundqvist, Björn Dahlöf
Läkartidningen - 2015-01-01
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: A LIFE
substudy

J. K. K. Vishram, Björn Dahlöf, R. B. Devereux, H. Ibsen, S. E. Kjeldsen, L. H. Lindholm, G. Mancia, P. M. Okin, P. M. Rothwell, K. Wachtell, M. H. Olsen
Journal of Hypertension - 2015-01-01
Potential Clinical Application of Angiotensin 2 Receptor
Agonists

N. Marina, Björn Dahlöf, B. Williams
The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications - 2015-01-01
Physician (investigator) inertia in apparent treatment-resistant hypertension - Insights from large randomized clinical
trials

S. E. Kjeldsen, S. Julius, Björn Dahlöf, M. A. Weber
Blood Pressure - 2015-01-01
Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH
Trial

P. H. Skoglund, P. Svensson, J. Asp, Björn Dahlöf, S. E. Kjeldsen, K. A. Jamerson, M. A. Weber, Y. Jia, D. H. Zappe, J. Ostergren
The Journal of Clinical Hypertension - 2015-01-01
NeuroThera((R)) Efficacy and Safety Trial - 3 (NEST-3): a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera((R)) Laser System for the treatment of acute ischemic stroke within 24 h of stroke
onset

J. A. Zivin, R. Sehra, A. Shoshoo, G. W. Albers, N. M. Bornstein, Björn Dahlöf, S. E. Kasner, G. Howard, A. Shuaib, J. Streeter, S. P. Richieri, W. Hacke
International journal of stroke : official journal of the International Stroke Society - 2014-01-01
Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive
treatment

P. M. Okin, D. A. Hille, S. E. Kjeldsen, Björn Dahlöf, R. B. Devereux
Blood pressure - 2014-01-01
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive
therapy

P. M. Okin, C. N. Bang, K. Wachtell, D. A. Hille, S. E. Kjeldsen, S. Julius, Björn Dahlöf, R. B. Devereux
American Journal of Hypertension - 2014-01-01
Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor beta1 in the rat
heart

D. Lauer, S. Slavic, M. Sommerfeld, C. Thone-Reineke, Y. Sharkovska, A. Hallberg, Björn Dahlöf, U. Kintscher, T. Unger, U. M. Steckelings, E. Kaschina
Hypertension - 2014-01-01
Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention
study

C. J. Estol, P. M. Bath, P. B. Gorelick, D. Cotton, R. H. Martin, M. A. Weber, Björn Dahlöf
Blood Pressure Monitoring - 2014-01-01
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive
patients

C. N. Bang, E. Gerdts, G. P. Aurigemma, K. Boman, G. de Simone, Björn Dahlöf, L. Kober, K. Wachtell, R. B. Devereux
Circulation Cardiovascular Imaging - 2014-01-01
Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty
rats

G. Castoldi, C. R. di Gioia, C. Bombardi, S. Maestroni, R. Carletti, U. M. Steckelings, Björn Dahlöf, T. Unger, G. Zerbini, A. Stella
American Journal of Physiology - Renal Physiology - 2014-01-01
Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart
failure

P. M. Okin, K. Wachtell, E. Gerdts, Björn Dahlöf, R. B. Devereux
Journal of Hypertension - 2014-01-01
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE
study)

C. Mancusi, E. Gerdts, G. de Simone, Y. M. Abdelhai, M. T. Lonnebakken, K. Boman, K. Wachtell, Björn Dahlöf, R. B. Devereux
Blood Pressure - 2014-01-01
Transcranial Laser Therapy in Acute Stroke Treatment Results of Neurothera Effectiveness and Safety Trial 3, a Phase III Clinical End Point Device
Trial

W. Hacke, P. D. Schellinger, G. W. Albers, N. M. Bornstein, Björn Dahlöf, R. Fulton, S. E. Kasner, A. Shuaib, S. P. Richieri, S. G. Dilly, J. Zivin, K. R. Lees
Stroke - 2014-01-01
Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension
study

C. N. Bang, E. Gerdts, G. P. Aurigemma, K. Boman, Björn Dahlöf, M. J. Roman, L. Kober, K. Wachtell, R. B. Devereux
Journal of hypertension - 2013-01-01
ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial
data

D. Prieto-Merino, J. Dobson, A. K. Gupta, C. L. Chang, P. S. Sever, Björn Dahlöf, H. Wedel, S. Pocock, N. Poulter
Journal of Human Hypertension - 2013-01-01
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF
expression

P. Namsolleck, F. Boato, K. Schwengel, L. Paulis, K. Matho, N. Geurts, C. Thone-Reineke, K. Lucht, K. Seidel, A. Hallberg, Björn Dahlöf, T. Unger, S. Hendrix, U. M. Steckelings
Neurobiology of disease - 2013-01-01
Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular
hypertrophy

F. Fyhrquist, A. Eriksson, O. Saijonmaa, B. G. Nordestgaard, K. Kontula, U. de Faire, H. Ibsen, S. Kjeldsen, I. Os, Björn Dahlöf
Journal of the renin-angiotensin-aldosterone system : JRAAS - 2013-01-01
Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure
goals

S. Neldam, Björn Dahlöf, W. Oigman, H. Schumacher
International journal of clinical practice - 2013-01-01
The Effects of Telmisartan and Amlodipine in Treatment-Naive and Previously Treated Hypertensive Patients: A Subanalysis from a 4 x 4 Factorial Design
Study

H. A. Punzi, Björn Dahlöf, D. Webster, C. R. Majul, W. Oigman, R. Olvera, M. Seeber, M. Kobe, H. Schumacher
Clinical and experimental hypertension - 2013-01-01
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular
hypertrophy

P. M. Okin, C. N. Bang, K. Wachtell, D. A. Hille, S. E. Kjeldsen, Björn Dahlöf, R. B. Devereux
Circulation. Arrhythmia and electrophysiology - 2013-01-01
Systolic blood pressure and cardiovascular outcomes during treatment of
hypertension

M. A. Weber, G. L. Bakris, A. Hester, M. R. Weir, T. A. Hua, D. Zappe, Björn Dahlöf, E. J. Velazquez, B. Pitt, K. Jamerson
The American journal of medicine - 2013-01-01
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery
disease

G. Bakris, A. Briasoulis, Björn Dahlöf, K. Jamerson, M. A. Weber, R. Y. Kelly, A. Hester, T. Hua, D. Zappe, B. Pitt
The American journal of cardiology - 2013-01-01
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: The LIFE
Study

P. M. Okin, D. A. Hille, B. P. Wiik, S. E. Kjeldsen, L. H. Lindholm, Björn Dahlöf, R. B. Devereux
Diabetic medicine : a journal of the British Diabetic Association - 2013-01-01
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled
trial

M. A. Weber, K. Jamerson, G. L. Bakris, M. R. Weir, D. Zappe, Y. Zhang, Björn Dahlöf, E. J. Velazquez, B. Pitt
Lancet - 2013-01-01
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE
study

M. De Marco, E. Gerdts, G. Casalnuovo, T. Migliore, K. Wachtell, K. Boman, Björn Dahlöf, M. H. Olsen, J. R. Kizer, R. B. Devereux, G. de Simone
American journal of hypertension - 2013-01-01
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass
regression

O. Vardeny, A. C. Pouleur, M. Takeuchi, E. Appelbaum, A. Verma, M. Prescott, B. Smith, Björn Dahlöf, S. D. Solomon
Journal of the renin-angiotensin-aldosterone system : JRAAS - 2012-01-01
Renal outcomes in hypertensive Black patients at high cardiovascular
risk

M. R. Weir, G. L. Bakris, M. A. Weber, Björn Dahlöf, R. B. Devereux, S. E. Kjeldsen, B. Pitt, J. T. Wright, R. Y. Kelly, T. A. Hua, R. A. Hester, E. Velazquez, K. A. Jamerson
Kidney international - 2012-01-01
Direct stimulation of angiotensin II type 2 receptor enhances spatial
memory

F. Jing, M. Mogi, A. Sakata, J. Iwanami, K. Tsukuda, K. Ohshima, L. J. Min, U. M. Steckelings, T. Unger, Björn Dahlöf, M. Horiuchi
Journal of cerebral blood flow and metabolism - 2012-01-01
Direct Angiotensin II Type 2 Receptor Stimulation Ameliorates Insulin Resistance in Type 2 Diabetes Mice with PPARgamma
Activation

K. Ohshima, M. Mogi, F. Jing, J. Iwanami, K. Tsukuda, L. J. Min, A. Ogimoto, Björn Dahlöf, U. M. Steckelings, T. Unger, J. Higaki, M. Horiuchi
PloS one - 2012-01-01
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension
study

A. C. Larstorp, I. Ariansen, K. Gjesdal, M. H. Olsen, H. Ibsen, R. B. Devereux, P. M. Okin, Björn Dahlöf, S. E. Kjeldsen, K. Wachtell
Hypertension - 2012-01-01
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE
study

A. C. Larstorp, P. M. Okin, R. B. Devereux, M. H. Olsen, H. Ibsen, Björn Dahlöf, S. E. Kjeldsen, K. Wachtell
American journal of hypertension - 2012-01-01
Effect of Changing Heart Rate During Treatment of Hypertension on Incidence of Heart
Failure

P. M. Okin, S. E. Kjeldsen, S. Julius, D. A. Hille, Björn Dahlöf, R. B. Devereux
The American journal of cardiology - 2012-01-01
Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: The LIFE
study

P. M. Okin, S. E. Kjeldsen, S. Julius, Björn Dahlöf, R. B. Devereux
Heart rhythm - 2012-01-01
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: The LIFE
Study

I. Ariansen, H. M. Reims, K. Gjesdal, M. H. Olsen, H. Ibsen, R. B. Devereux, P. M. Okin, S. E. Kjeldsen, Björn Dahlöf, K. Wachtell
Blood pressure - 2012-01-01
Direct angiotensin II type 2 receptor stimulation in Nomega-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic
remodeling

L. Paulis, S. T. Becker, K. Lucht, K. Schwengel, S. Slavic, E. Kaschina, C. Thone-Reineke, Björn Dahlöf, J. Baulmann, T. Unger, U. M. Steckelings
Hypertension - 2012-01-01
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum
potassium

P. M. Okin, S. E. Kjeldsen, L. H. Lindholm, Björn Dahlöf, R. B. Devereux
Blood pressure - 2012-01-01
Impact of lower achieved blood pressure on outcomes in hypertensive
patients

P. M. Okin, D. A. Hille, S. E. Kjeldsen, Björn Dahlöf, R. B. Devereux
Journal of hypertension - 2012-01-01
Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular
hypertrophy

E. Gerdts, P. M. Okin, K. Boman, K. Wachtell, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
American journal of hypertension - 2012-01-01
Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN
study

J. M. Neutel, G. Mancia, H. R. Black, Björn Dahlöf, H. Defeo, L. Ley, R. Vinisko
Journal of clinical hypertension - 2012-01-01
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE)
study

A. C. Ruwald, B. Westergaard, T. Sehestedt, S. E. Kjeldsen, L. H. Lindholm, K. Wachtell, R. B. Devereux, H. Ibsen, M. S. Nieminen, Björn Dahlöf, M. H. Olsen
Journal of hypertension - 2012-01-01
Impact of overweight and obesity on cardiac benefit of antihypertensive
treatment

E. Gerdts, G. de Simone, B. P. Lund, P. M. Okin, K. Wachtell, K. Boman, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
Nutrition, metabolism, and cardiovascular diseases : NMCD - 2011-01-01
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with
hypertension

A. C. Pouleur, H. Uno, M. F. Prescott, A. Desai, E. Appelbaum, V. Lukashevich, B. A. Smith, Björn Dahlöf, S. D. Solomon
Journal of the renin-angiotensin-aldosterone system : JRAAS - 2011-01-01
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE
study

P. M. Okin, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, M. S. Nieminen, J. M. Edelman, Björn Dahlöf, R. B. Devereux
European journal of heart failure - 2011-01-01
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering
Arm

D. J. Collier, N. R. Poulter, Björn Dahlöf, P. S. Sever, H. Wedel, J. Buch, M. J. Caulfield
Journal of hypertension - 2011-01-01
Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm
(ASCOT-BPLA)

D. J. Collier, N. R. Poulter, Björn Dahlöf, P. S. Sever, H. Wedel, J. Buch, M. J. Caulfield
Journal of hypertension - 2011-01-01
Racial differences in incident heart failure during antihypertensive
therapy

P. M. Okin, S. E. Kjeldsen, Björn Dahlöf, R. B. Devereux
Circulation. Cardiovascular quality and outcomes - 2011-01-01
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE
substudy

M. H. Olsen, K. Wachtell, H. Ibsen, L. Lindholm, S. E. Kjeldsen, P. Omvik, M. S. Nieminen, Björn Dahlöf, P. M. Okin, R. B. Devereux
Journal of hypertension - 2011-01-01
Generic and therapeutic substitution: a viewpoint on achieving best practice in
Europe

A. Johnston, R. Asmar, Björn Dahlöf, K. Hill, D. A. Jones, J. Jordan, M. Livingston, G. Macgregor, M. Sobanja, P. Stafylas, E. A. Rosei, J. Zamorano
British journal of clinical pharmacology - 2011-01-01
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE
study

F. Fyhrquist, K. Silventoinen, O. Saijonmaa, K. Kontula, R. B. Devereux, U. de Faire, I. Os, Björn Dahlöf
Journal of human hypertension - 2011-01-01
In-treatment stroke volume predicts cardiovascular risk in
hypertension

M. T. Lonnebakken, E. Gerdts, K. Boman, K. Wachtell, Björn Dahlöf, R. B. Devereux
Journal of hypertension - 2011-01-01
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT)

N. Chapman, C. L. Chang, M. Caulfield, Björn Dahlöf, G. Feder, P. S. Sever, N. R. Poulter
Ethnicity & disease - 2011-01-01
Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel
approach

A. K. Gupta, D. Prieto-Merino, Björn Dahlöf, P. S. Sever, N. R. Poulter
Diabetic medicine : a journal of the British Diabetic Association - 2011-01-01
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH
Study

S. E. Kjeldsen, K. A. Jamerson, G. L. Bakris, B. Pitt, Björn Dahlöf, E. J. Velazquez, T. A. Hua, R. Y. Kelly, D. Zappe, A. Hester, J. Tuomilehto, J. Ostergren, H. Ibsen, M. Weber
Blood pressure - 2011-01-01
Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive
patients

R. M. Guthrie, Björn Dahlöf, K. A. Jamerson, R. Olvera, M. Seeber, H. Schumacher, W. Oigman
Current medical research and opinion - 2011-01-01
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at
high-risk

A. K. Gupta, E. G. Nasothimiou, C. L. Chang, P. S. Sever, Björn Dahlöf, N. R. Poulter
Journal of hypertension - 2011-01-01
Non-peptide AT2-receptor
agonists

U. M. Steckelings, M. Larhed, A. Hallberg, R. E. Widdop, E. S. Jones, C. Wallinder, P. Namsolleck, Björn Dahlöf, T. Unger
Current opinion in pharmacology - 2011-01-01
Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24-Hour Ambulatory Systolic Blood Pressure
Control

K. A. Jamerson, R. Devereux, G. L. Bakris, Björn Dahlöf, B. Pitt, E. J. Velazquez, M. Weir, R. Y. Kelly, T. A. Hua, A. Hester, M. A. Weber
Hypertension - 2011-01-01
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE
study

A. C. Larstorp, P. M. Okin, R. B. Devereux, M. H. Olsen, H. Ibsen, Björn Dahlöf, S. E. Kjeldsen, K. Wachtell
Journal of Human Hypertension - 2011-01-01
Effects of Atenolol or Losartan on Fibrinolysis and von Willebrand Factor in Hypertensive Patients With Left Ventricular
Hypertrophy

K. Boman, J. Hernestal Boman, J. Andersson, M. Olofsson, Björn Dahlöf
Clinical and Applied Thrombosis/Hemostasis - 2010-01-01
Compound 21, the first orally active, selective agonist of the angiotensin II type 2 (AT2) receptor: implications for AT2 receptor research and therapeutic
potential

T. Unger, Björn Dahlöf
Journal of Renin-Angiotensin-Aldosterone System - 2010-01-01
Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart
Study

H. Yoshida, M. Shimizu, K. Ikewaki, I. Taniguchi, N. Tada, M. Yoshimura, G. Rosano, Björn Dahlöf, S. Mochizuki
Journal of Hypertension - 2010-01-01
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE
Study

B. P. Wiik, A. C. Larstorp, A. Hoieggen, S. E. Kjeldsen, M. H. Olsen, H. Ibsen, L. Lindholm, Björn Dahlöf, R. B. Devereux, P. M. Okin, K. Wachtell
American Journal of Hypertension - 2010-01-01
Cardiovascular events during differing hypertension therapies in patients with
diabetes

M. A. Weber, G. L. Bakris, K. Jamerson, M. Weir, S. E. Kjeldsen, R. B. Devereux, E. J. Velazquez, Björn Dahlöf, R. Y. Kelly, T. A. Hua, A. Hester, B. Pitt
Journal of the American College of Cardiology - 2010-01-01
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE
Study)

K. Wachtell, V. Palmieri, E. Gerdts, J. N. Bella, G. P. Aurigemma, V. Papademetriou, Björn Dahlöf, T. Aalto, H. Ibsen, J. E. Rokkedal, R. B. Devereux
American Journal of Cardiology - 2010-01-01
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction
study

K. Wachtell, E. Gerdts, V. Palmieri, M. H. Olsen, M. S. Nieminen, V. Papademetriou, K. Boman, Björn Dahlöf, G. P. Aurigemma, J. E. Rokkedal, R. B. Devereux
Journal of Hypertension - 2010-01-01
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE
Study

K. Wachtell, E. Gerdts, G. P. Aurigemma, K. Boman, Björn Dahlöf, M. S. Nieminen, M. H. Olsen, P. M. Okin, V. Palmieri, J. E. Rokkedal, R. B. Devereux
Blood Pressure - 2010-01-01
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE
Study

C. L. Soraas, K. Wachtell, P. M. Okin, Björn Dahlöf, R. B. Devereux, T. Tonnessen, S. E. Kjeldsen, M. H. Olsen
Blood Pressure - 2010-01-01
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular
hypertrophy

P. M. Okin, S. E. Kjeldsen, S. Julius, D. A. Hille, Björn Dahlöf, J. M. Edelman, R. B. Devereux
European Heart Journal - 2010-01-01
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive
patients

P. M. Okin, D. A. Hille, S. E. Kjeldsen, L. H. Lindholm, J. M. Edelman, Björn Dahlöf, R. B. Devereux
American Journal of Hypertension - 2010-01-01
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial
fibrillation

P. M. Okin, E. Gerdts, K. Wachtell, L. Oikarinen, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
Journal of Hypertension - 2010-01-01
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes
Trial

P. Lindgren, J. Eriksson, M. Buxton, T. Kahan, N. R. Poulter, Björn Dahlöf, P. S. Sever, H. Wedel, B. Jonsson
International Journal of Clinical Practice - 2010-01-01
Metabolic syndrome, independent of its components, is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the
ASCOT-BPLA

A. K. Gupta, Björn Dahlöf, P. S. Sever, N. R. Poulter
Diabetes Care - 2010-01-01
Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension
study

S. Cicala, G. de Simone, E. Gerdts, Björn Dahlöf, L. H. Lindholm, S. E. Kjeldsen, R. B. Devereux
Journal of Hypertension - 2010-01-01
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular
hypertrophy

K. Boman, J. H. Boman, J. Andersson, M. Olofsson, Björn Dahlöf
Clinical and Applied Thrombosis/Hemostasis - 2010-01-01
Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic
potential

T. Unger, Björn Dahlöf
Journal of the Renin-Angiotensin-Aldosterone System - 2010-01-01
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE
study

B. G. Nordestgaard, K. Kontula, M. Benn, Björn Dahlöf, U. de Faire, J. M. Edelman, E. Eliasson, F. Fyhrquist, D. A. Hille, H. Ibsen, P. A. Lyle, K. Berg, M. Sandberg, A. A. Sethi, P. H. Wong, I. Os
Pharmacogenet Genomics - 2010-01-01
Cardiovascular disease risk factors: epidemiology and risk
assessment

Björn Dahlöf
The American Journal of Cardiology - 2010-01-01
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor
kappaB

F. Rompe, M. Artuc, A. Hallberg, M. Alterman, K. Stroder, C. Thone-Reineke, A. Reichenbach, J. Schacherl, Björn Dahlöf, M. Bader, N. Alenina, M. Schwaninger, T. Zuberbier, H. Funke-Kaiser, C. Schmidt, W. H. Schunck, T. Unger, U. M. Steckelings
Hypertension - 2010-01-01
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled
trial

G. L. Bakris, P. A. Sarafidis, M. R. Weir, Björn Dahlöf, B. Pitt, K. Jamerson, E. J. Velazquez, L. Staikos-Byrne, R. Y. Kelly, V. Shi, Y. T. Chiang, M. A. Weber
The Lancet - 2010-01-01
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic
hypertension

P. M. Rothwell, S. C. Howard, E. Dolan, E. O'Brien, J. E. Dobson, Björn Dahlöf, P. S. Sever, N. R. Poulter
The Lancet - 2010-01-01
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of
stroke

P. M. Rothwell, S. C. Howard, E. Dolan, E. O'Brien, J. E. Dobson, Björn Dahlöf, N. R. Poulter, P. S. Sever
The Lancet Neurology - 2010-01-01
Guidelines for the management of atrial
fibrillation

A. John Camm, Paulus Kirchhof, Gregory Lip, Ulrich Schotten, Irene Savelieva, Sabine Ernst, Isabelle Van Gelder, Nawwar Al Attar, Gerhard Hindricks, Bernard Prendergast, Hein Heidbuchel, Ottavio Alfieri, Annalisa Angelini, Dan Atar, Paolo Colonna, Raffaele De Caterina, Johan De Sutter, Andreas Goette, Bulent Gorenek, Magnus Heldal, Stefan H. Hohloser, Philippe Kolh, Jean-Yves Le Heuzey, Piotr Ponikowski, Frans H. Rutten, Alec Vahanian, Angelo Auricchio, Jeroen Bax, Claudio Ceconi, Veronica Dean, Gerasimos Filippatos, Christian Funck-Brentano, Richard Hobbs, Peter Kearney, Theresa McDonagh, Bogdan A. Popescu, Zeljko Reiner, Udo Sechtem, Per Anton Sirnes, Michal Tendera, Panos E. Vardas, Petr Widimsky, Vazha Agladze, Etienne Aliot, Tosho Balabanski, Carina Blomstrom-Lundqvist, Alessandro Capucci, Harry Crijns, Björn Dahlöf, Thierry Folliguet, Michael Glikson, Marnix Goethals, Dietrich C. Gulba, Siew Yen Ho, Robert J. M. Klautz, Sedat Kose, John McMurray, Pasquale Perrone Filardi, Pekka Raatikainen, Maria Jesus Salvador, Martin J. Schalij, Alexander Shpektor, Joao Sousa, Janina Stepinska, Hasso Uuetoa, Jose Luis Zamorano, Igor Zupan
Europace - 2010-01-01
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes
Trial)

N. R. Poulter, J. E. Dobson, P. S. Sever, Björn Dahlöf, H. Wedel, N. R. Campbell
Journal of the American College of Cardiology - 2009-01-01
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE
study

P. M. Okin, R. B. Devereux, S. E. Kjeldsen, J. M. Edelman, Björn Dahlöf
Journal of Hypertension - 2009-01-01
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE
study

D. P. Morin, L. Oikarinen, M. Viitasalo, L. Toivonen, M. S. Nieminen, S. E. Kjeldsen, Björn Dahlöf, M. John, R. B. Devereux, P. M. Okin
European Heart Journal - 2009-01-01
Natriuretic peptides as indicators of cardiac remodeling in hypertensive
patients

M. Magnusson, S. Jovinge, E. Rydberg, Björn Dahlöf, C. Hall, O. W. Nielsen, A. Grubb, R. Willenheimer
Blood Press - 2009-01-01
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension
study

S. E. Kjeldsen, R. B. Devereux, D. A. Hille, P. A. Lyle, Björn Dahlöf, S. Julius, J. M. Edelman, S. M. Snapinn, U. de Faire, F. Fyhrquist, H. Ibsen, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel
Blood Press - 2009-01-01
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE
study)

E. Gerdts, S. Franklin, A. Rieck, V. Papademetriou, K. Wachtell, M. Nieminen, Björn Dahlöf, R. B. Devereux
Blood Press - 2009-01-01
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE
echo-substudy)

M. Chinali, G. P. Aurigemma, G. de Simone, R. K. Mishra, E. Gerdts, K. Wachtell, K. Boman, Björn Dahlöf, R. B. Devereux
The American Journal of Cardiology - 2009-01-01
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE)
study

M. H. Olsen, K. Wachtell, G. Beevers, Björn Dahlöf, R. B. Devereux, U. de Faire, F. Fyhrquist, H. Ibsen, S. E. Kjeldsen, O. Lederballe-Pedersen, L. H. Lindholm, P. Narayan, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel
American Heart Journal - 2009-01-01
Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular
events

T. Sawada, T. Takahashi, H. Yamada, Björn Dahlöf, H. Matsubara
Journal of Human Hypertension - 2009-01-01
Management of cardiovascular risk with RAS inhibitor/CCB combination
therapy

Björn Dahlöf
Journal of Human Hypertension - 2009-01-01
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular
hypertrophy

S. D. Solomon, E. Appelbaum, W. J. Manning, A. Verma, Tommy Berglund, V. Lukashevich, C. Cherif Papst, B. A. Smith, Björn Dahlöf
Circulation - 2009-01-01
Coronary heart disease benefits from blood pressure and
lipid-lowering

P. S. Sever, N. R. Poulter, S. Mastorantonakis, C. L. Chang, Björn Dahlöf, H. Wedel
International Journal of Cardiology - 2009-01-01
Effectiveness and safety of transcranial laser therapy for acute ischemic
stroke

J. A. Zivin, G. W. Albers, N. Bornstein, T. Chippendale, Björn Dahlöf, T. Devlin, M. Fisher, W. Hacke, W. Holt, S. Ilic, S. Kasner, R. Lew, M. Nash, J. Perez, M. Rymer, P. Schellinger, D. Schneider, S. Schwab, R. Veltkamp, M. Walker, J. Streeter
Stroke - 2009-01-01
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension
study

M. H. Olsen, K. Wachtell, G. Beevers, Björn Dahlöf, G. de Simone, R. B. Devereux, U. de Faire, F. Fyhrquist, H. Ibsen, S. E. Kjeldsen, O. Lederballe-Pedersen, L. H. Lindholm, P. A. Lyle, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel
Journal of Hypertension - 2009-01-01
Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE
study

E. Gerdts, P. M. Okin, P. Omvik, K. Wachtell, Björn Dahlöf, P. Hildebrandt, M. S. Nieminen, R. B. Devereux
Nutr Metab Cardiovasc Dis - 2009-01-01
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm
extension

P. S. Sever, N. R. Poulter, Björn Dahlöf, H. Wedel
Journal of Hypertension - 2009-01-01
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study
(LIFE)

P. M. Okin, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, M. S. Nieminen, J. M. Edelman, Björn Dahlöf, R. B. Devereux
Circulation - 2009-01-01
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from
ASCOT1

P. Lindgren, M. Buxton, T. Kahan, N. R. Poulter, Björn Dahlöf, P. S. Sever, H. Wedel, B. Jonsson
Pharmacoeconomics - 2009-01-01
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE
study

G. de Simone, P. M. Okin, E. Gerdts, M. H. Olsen, K. Wachtell, D. A. Hille, Björn Dahlöf, S. E. Kjeldsen, R. B. Devereux
Nutr Metab Cardiovasc Dis - 2009-01-01
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE
study

K. Boman, E. Gerdts, K. Wachtell, Björn Dahlöf, M. S. Nieminen, M. Olofsson, V. Papademetriou, R. B. Devereux
Eur J Cardiovasc Prev Rehabil - 2009-01-01
Telmisartan to prevent recurrent stroke and cardiovascular
events

S. Yusuf, H. C. Diener, R. L. Sacco, D. Cotton, S. Ounpuu, W. A. Lawton, Y. Palesch, R. H. Martin, G. W. Albers, P. Bath, N. Bornstein, B. P. Chan, S. T. Chen, L. Cunha, Björn Dahlöf, J. De Keyser, G. A. Donnan, C. Estol, P. Gorelick, V. Gu, K. Hermansson, L. Hilbrich, M. Kaste, C. Lu, T. Machnig, P. Pais, R. Roberts, V. Skvortsova, P. Teal, D. Toni, C. VanderMaelen, T. Voigt, M. Weber, B. W. Yoon
New England Journal of Medicine - 2008-01-01
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial
infarction?

E. Kaschina, A. Grzesiak, J. Li, A. Foryst-Ludwig, M. Timm, F. Rompe, M. Sommerfeld, U. R. Kemnitz, C. Curato, P. Namsolleck, C. Tschope, A. Hallberg, M. Alterman, T. Hucko, I. Paetsch, T. Dietrich, B. Schnackenburg, K. Graf, Björn Dahlöf, U. Kintscher, T. Unger, U. M. Steckelings
Circulation - 2008-01-01
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors.
Introduction

E. Ritz, Björn Dahlöf
Nature Clinical Practice Cardiovascular Medicine - 2008-01-01
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled
study

H. C. Diener, R. L. Sacco, S. Yusuf, D. Cotton, S. Ounpuu, W. A. Lawton, Y. Palesch, R. H. Martin, G. W. Albers, P. Bath, N. Bornstein, B. P. Chan, S. T. Chen, L. Cunha, Björn Dahlöf, J. De Keyser, G. A. Donnan, C. Estol, P. Gorelick, V. Gu, K. Hermansson, L. Hilbrich, M. Kaste, C. Lu, T. Machnig, P. Pais, R. Roberts, V. Skvortsova, P. Teal, D. Toni, C. VanderMaelen, T. Voigt, M. Weber, B. W. Yoon
Lancet Neurology - 2008-01-01
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II
diabetes

J. Ostergren, N. R. Poulter, P. S. Sever, Björn Dahlöf, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien
Journal of Hypertension - 2008-01-01
The Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH)
Trial

G. Bakris, A. Hester, M. Weber, Björn Dahlöf, B. Pitt, E. Velasquez, L. Staikos-Byrne, V. Shi, K. Jamerson
Journal of the CardioMetabolic Syndrome - 2008-01-01
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk
patients

K. Jamerson, M. A. Weber, G. L. Bakris, Björn Dahlöf, B. Pitt, V. Shi, A. Hester, J. Gupte, M. Gatlin, E. J. Velazquez
New England Journal of Medicine - 2008-01-01
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent
stroke

R. L. Sacco, H. C. Diener, S. Yusuf, D. Cotton, S. Ounpuu, W. A. Lawton, Y. Palesch, R. H. Martin, G. W. Albers, P. Bath, N. Bornstein, B. P. Chan, S. T. Chen, L. Cunha, Björn Dahlöf, J. De Keyser, G. A. Donnan, C. Estol, P. Gorelick, V. Gu, K. Hermansson, L. Hilbrich, M. Kaste, C. Lu, T. Machnig, P. Pais, R. Roberts, V. Skvortsova, P. Teal, D. Toni, C. VanderMaelen, T. Voigt, M. Weber, B. W. Yoon
New England Journal of Medicine - 2008-01-01
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based
regimen

P. Lindgren, M. Buxton, T. Kahan, N. R. Poulter, Björn Dahlöf, P. S. Sever, H. Wedel, B. Jonsson
Heart - 2008-01-01
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial
closure

P. S. Sever, N. R. Poulter, Björn Dahlöf, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. E. Kjeldsen, A. Kristinsson, G. McInnes, J. Mehlsen, M. S. Nieminen, E. T. O'Brien, J. Ostergren
European Heart Journal - 2008-01-01
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE
study

P. M. Okin, K. Wachtell, R. B. Devereux, M. S. Nieminen, L. Oikarinen, M. Viitasalo, L. Toivonen, H. Ibsen, M. H. Olsen, K. Borch-Johnsen, L. H. Lindholm, S. E. Kjeldsen, S. Julius, Björn Dahlöf
American Journal of Hypertension - 2008-01-01
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive
medication

A. K. Gupta, Björn Dahlöf, J. Dobson, P. S. Sever, H. Wedel, N. R. Poulter
Diabetes Care - 2008-01-01
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension
Study

I. Os, V. Franco, S. E. Kjeldsen, Karin Manhem, R. B. Devereux, E. Gerdts, D. A. Hille, P. A. Lyle, P. M. Okin, Björn Dahlöf, S. Oparil
Hypertension - 2008-01-01
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE
study

S. Cicala, G. de Simone, K. Wachtell, E. Gerdts, K. Boman, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
Journal of Hypertension - 2008-01-01
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life
study

V. Palmieri, J. N. Bella, E. Gerdts, K. Wachtell, V. Papademetriou, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
American Journal of Hypertension - 2008-01-01
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension
study

Z. Li, Björn Dahlöf, P. M. Okin, S. E. Kjeldsen, K. Wachtell, H. Ibsen, M. S. Nieminen, Sverker Jern, R. B. Devereux
Journal of Hypertension - 2008-01-01
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE
study)

E. Gerdts, D. Cramariuc, G. de Simone, K. Wachtell, Björn Dahlöf, R. B. Devereux
European Heart Journal – Cardiovascular Imaging - 2008-01-01
Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive
therapy

P. M. Okin, E. Gerdts, S. E. Kjeldsen, S. Julius, J. M. Edelman, Björn Dahlöf, R. B. Devereux
Hypertension - 2008-01-01
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE
study

M. Chinali, G. de Simone, K. Wachtell, E. Gerdts, J. M. Gardin, K. Boman, M. S. Nieminen, V. Papademetriou, Björn Dahlöf, R. B. Devereux
Journal of Hypertension - 2008-01-01
Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes
Trial

N. Chapman, C. L. Chang, Björn Dahlöf, P. S. Sever, H. Wedel, N. R. Poulter
Circulation - 2008-01-01
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH
study

S. E. Kjeldsen, K. A. Jamerson, G. L. Bakris, B. Pitt, Björn Dahlöf, E. J. Velazquez, J. Gupte, L. Staikos, T. A. Hua, V. Shi, A. Hester, J. Tuomilehto, J. Ostergren, H. Ibsen, M. Weber
Blood Pressure - 2008-01-01
Hypertoni

Mats Börjesson, Björn Dahlöf, S Kjeldsen
FYSS. Folkhälsoinstitutet, 2nd Ed - 2008-01-01
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE
study

E. Fossum, G. W. Gleim, S. E. Kjeldsen, J. R. Kizer, S. Julius, R. B. Devereux, W. E. Brady, D. A. Hille, P. A. Lyle, Björn Dahlöf
J Intern Med - 2007-01-01
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE
study

G. de Simone, M. H. Olsen, K. Wachtell, D. A. Hille, Björn Dahlöf, H. Ibsen, S. E. Kjeldsen, P. A. Lyle, R. B. Devereux
J Hum Hypertens - 2007-01-01
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular
risk

M. A. Weber, G. L. Bakris, Björn Dahlöf, B. Pitt, E. Velazquez, J. Gupte, M. Lefkowitz, A. Hester, V. Shi, M. Weir, S. Kjeldsen, B. Massie, S. Nesbitt, E. Ofili, K. Jamerson
Blood Press - 2007-01-01
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE
Study

K. Wachtell, P. M. Okin, M. H. Olsen, Björn Dahlöf, R. B. Devereux, H. Ibsen, S. E. Kjeldsen, L. H. Lindholm, M. S. Nieminen, K. Thygesen
Circulation - 2007-01-01
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE
study)

M. L. Smebye, E. K. Iversen, A. Hoieggen, A. Flaa, I. Os, S. E. Kjeldsen, M. H. Olsen, A. Chattopadhyay, D. A. Hille, P. A. Lyle, R. B. Devereux, Björn Dahlöf
Am J Cardiol - 2007-01-01
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE
Study

V. Palmieri, P. M. Okin, G. de Simone, J. N. Bella, K. Wachtell, E. Gerdts, K. Boman, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
J Hypertens - 2007-01-01
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive
patients

P. M. Okin, R. B. Devereux, K. E. Harris, Sverker Jern, S. E. Kjeldsen, S. Julius, J. M. Edelman, Björn Dahlöf
Ann Intern Med - 2007-01-01
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Study

P. M. Okin, R. B. Devereux, K. E. Harris, Sverker Jern, S. E. Kjeldsen, L. H. Lindholm, Björn Dahlöf
Hypertension - 2007-01-01
Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1
(NEST-1)

Y. Lampl, J. A. Zivin, M. Fisher, R. Lew, Lennart Welin, Björn Dahlöf, P. Borenstein, B. Andersson, J. Perez, C. Caparo, S. Ilic, U. Oron
Stroke - 2007-01-01
Exceptional early blood pressure control rates: the ACCOMPLISH
trial

K. Jamerson, G. L. Bakris, Björn Dahlöf, B. Pitt, E. Velazquez, J. Gupte, M. Lefkowitz, A. Hester, V. Shi, S. E. Kjeldsen, W. Cushman, V. Papademetriou, M. Weber
Blood Press - 2007-01-01
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension
trial

E. Gerdts, K. Wachtell, P. Omvik, J. E. Otterstad, L. Oikarinen, K. Boman, Björn Dahlöf, R. B. Devereux
Hypertension - 2007-01-01
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE
studies

W. B. Eijkelkamp, Z. Zhang, B. M. Brenner, M. E. Cooper, R. B. Devereux, Björn Dahlöf, H. Ibsen, W. F. Keane, L. H. Lindholm, M. H. Olsen, H. H. Parving, G. Remuzzi, S. Shahinfar, S. M. Snapinn, K. Wachtell, D. de Zeeuw
J Hypertens - 2007-01-01
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular
hypertrophy

R. B. Devereux, U. de Faire, F. Fyhrquist, K. E. Harris, H. Ibsen, S. E. Kjeldsen, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel, D. A. Hille, Björn Dahlöf
Curr Med Res Opin - 2007-01-01
Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the
future?

Björn Dahlöf, R. B. Devereux, S. E. Kjeldsen, P. A. Lyle, Z. Zhang, J. M. Edelman
Blood Press - 2007-01-01
Prevention of stroke in patients with
hypertension

Björn Dahlöf
Am J Cardiol - 2007-01-01
Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE
Study

S. Cicala, R. B. Devereux, G. de Simone, K. Wachtell, E. Gerdts, K. Boman, M. S. Nieminen, V. Papademetriou, Björn Dahlöf, P. M. Okin
Am J Hypertens - 2007-01-01
Effect of spironolactone on blood pressure in subjects with resistant
hypertension

N. Chapman, J. Dobson, S. Wilson, Björn Dahlöf, P. S. Sever, H. Wedel, N. R. Poulter
Hypertension - 2007-01-01
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes
Trial

P. Sever, Björn Dahlöf, N. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. McInnes, J. Mehlsen, M. Nieminem, E. O'Brien, J. Ostergren
Eur Heart J - 2006-01-01
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE
study

V. Palmieri, P. M. Okin, J. N. Bella, K. Wachtell, L. Oikarinen, E. Gerdts, K. Boman, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
J Hypertens - 2006-01-01
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE
study

M. H. Olsen, K. Wachtell, Björn Dahlöf, R. B. Devereux, H. Ibsen, S. E. Kjeldsen, L. H. Lindholm, P. A. Lyle, M. S. Nieminen
J Hum Hypertens - 2006-01-01
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE
study

M. H. Olsen, K. Wachtell, H. Ibsen, L. H. Lindholm, Björn Dahlöf, R. B. Devereux, S. E. Kjeldsen, L. Oikarinen, P. M. Okin
J Hypertens - 2006-01-01
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE
substudy

M. H. Olsen, K. Wachtell, O. W. Nielsen, C. Hall, R. Wergeland, H. Ibsen, S. E. Kjeldsen, R. B. Devereux, Björn Dahlöf, P. R. Hildebrandt
J Hypertens - 2006-01-01
Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
study

P. M. Okin, R. B. Devereux, M. S. Nieminen, Sverker Jern, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, Björn Dahlöf
Circulation - 2006-01-01
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension
Study

P. M. Okin, R. B. Devereux, E. Gerdts, S. M. Snapinn, K. E. Harris, Sverker Jern, S. E. Kjeldsen, S. Julius, J. M. Edelman, L. H. Lindholm, Björn Dahlöf
Circulation - 2006-01-01
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with
hypertension

P. M. Okin, K. Wachtell, R. B. Devereux, K. E. Harris, Sverker Jern, S. E. Kjeldsen, S. Julius, L. H. Lindholm, M. S. Nieminen, J. M. Edelman, D. A. Hille, Björn Dahlöf
Jama - 2006-01-01
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension
Study

P. Narayan, V. Papademetriou, K. Wachtell, E. Gerdts, K. Boman, M. S. Nieminen, G. de Simone, Björn Dahlöf, F. Fyhrquist, A. Hoieggen, R. B. Devereux
Hypertension - 2006-01-01
Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic
substudy

P. Lindgren, T. Kahan, N. Poulter, M. Buxton, P. Svarvar, Björn Dahlöf, B. Jonsson
Eur J Health Econ - 2006-01-01
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE
study

H. Ibsen, M. H. Olsen, K. Wachtell, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, Björn Dahlöf, S. M. Snapinn, Y. Wan, P. A. Lyle
Diabetes Care - 2006-01-01
Metabolic syndrome, new onset diabetes, and new end points in cardiovascular
trials

S. M. Haffner, L. Ruilope, Björn Dahlöf, E. Abadie, S. Kupfer, F. Zannad
J Cardiovasc Pharmacol - 2006-01-01
Prospects for the prevention of
stroke

Björn Dahlöf
J Hypertens Suppl - 2006-01-01
[Physical activity has a key role in hypertension
therapy]

Mats Börjesson, Björn Dahlöf
Lakartidningen - 2005-01-01
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension)
study

G. de Simone, K. Wachtell, V. Palmieri, D. A. Hille, G. Beevers, Björn Dahlöf, U. de Faire, F. Fyhrquist, H. Ibsen, S. Julius, S. E. Kjeldsen, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, R. B. Devereux
Circulation - 2005-01-01
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE)
study

K. Wachtell, M. Lehto, E. Gerdts, M. H. Olsen, Björn Hornestam, Björn Dahlöf, H. Ibsen, S. Julius, S. E. Kjeldsen, L. H. Lindholm, M. S. Nieminen, R. B. Devereux
J Am Coll Cardiol - 2005-01-01
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE)
study

K. Wachtell, Björn Hornestam, M. Lehto, D. J. Slotwiner, E. Gerdts, M. H. Olsen, P. Aurup, Björn Dahlöf, H. Ibsen, S. Julius, S. E. Kjeldsen, L. H. Lindholm, M. S. Nieminen, J. Rokkedal, R. B. Devereux
J Am Coll Cardiol - 2005-01-01
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm
(ASCOT-LLA)

P. S. Sever, N. R. Poulter, Björn Dahlöf, H. Wedel
Am J Cardiol - 2005-01-01
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm
(ASCOT-LLA)

P. S. Sever, N. R. Poulter, Björn Dahlöf, H. Wedel, R. Collins, G. Beevers, M. Caulfield, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren
Diabetes Care - 2005-01-01
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm
(ASCOT-BPLA)

N. R. Poulter, H. Wedel, Björn Dahlöf, P. S. Sever, D. G. Beevers, M. Caulfield, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren, S. Pocock
Lancet - 2005-01-01
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE)
substudy

M. H. Olsen, K. Wachtell, J. N. Bella, V. Palmieri, E. Gerdts, G. Smith, M. S. Nieminen, Björn Dahlöf, H. Ibsen, R. B. Devereux
Am J Hypertens - 2005-01-01
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm
(ASCOT-LLA)

P. Lindgren, M. Buxton, T. Kahan, N. R. Poulter, Björn Dahlöf, P. S. Sever, H. Wedel, B. Jonsson
Eur J Cardiovasc Prev Rehabil - 2005-01-01
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers

S. E. Kjeldsen, P. A. Lyle, A. M. Tershakovec, R. B. Devereux, S. Oparil, Björn Dahlöf, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, H. Wedel
Expert Opin Emerg Drugs - 2005-01-01
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE
study

S. E. Kjeldsen, P. A. Lyle, J. R. Kizer, Björn Dahlöf, R. B. Devereux, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, S. M. Snapinn, K. E. Harris, H. Wedel
J Clin Hypertens (Greenwich) - 2005-01-01
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension
study

J. R. Kizer, Björn Dahlöf, S. E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel, K. Wachtell, J. M. Edelman, S. M. Snapinn, K. E. Harris, R. B. Devereux
Hypertension - 2005-01-01
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE
trial

B. Jonsson, G. W. Carides, T. A. Burke, E. J. Dasbach, L. H. Lindholm, Björn Dahlöf
J Hypertens - 2005-01-01
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension
study

H. Ibsen, M. H. Olsen, K. Wachtell, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, Björn Dahlöf, R. B. Devereux, U. de Faire, F. Fyhrquist, S. Julius, S. E. Kjeldsen, O. Lederballe-Pedersen, M. S. Nieminen, P. Omvik, S. Oparil, Y. Wan
Hypertension - 2005-01-01
Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE
study

P. Hildebrandt, K. Wachtell, Björn Dahlöf, V. Papademitriou, E. Gerdts, T. Giles, L. Oikarinen, C. Tuxen, M. H. Olsen, R. B. Devereux
Diabet Med - 2005-01-01
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular
hypertrophy

F. Fyhrquist, Björn Dahlöf, R. B. Devereux, S. E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, D. A. Hille, P. A. Lyle, J. M. Edelman, S. M. Snapinn, H. Wedel
Hypertension - 2005-01-01
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE
substudy

S. S. Franklin, K. Wachtell, V. Papademetriou, M. H. Olsen, R. B. Devereux, F. Fyhrquist, H. Ibsen, S. E. Kjeldsen, Björn Dahlöf
Hypertension - 2005-01-01
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE)
study

E. Fossum, A. Moan, S. E. Kjeldsen, R. B. Devereux, S. Julius, S. M. Snapinn, J. M. Edelman, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel, Björn Dahlöf
J Am Coll Cardiol - 2005-01-01
Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure
reduction

Björn Dahlöf, A. Degl' Innocenti, D. Elmfeldt, J. G. Puig, T. Gundersen, J. Hosie, W. Januszewicz, C. J. Lindstrom, D. Magometschnigg, P. Tanser, P. Toutouzas, B. Waeber, I. Wiklund
Am J Hypertens - 2005-01-01
Further evidence for low-dose combinations in patients with left ventricular
hypertrophy

Björn Dahlöf
J Hum Hypertens - 2005-01-01
[Hypertension therapy with beta blocker plus diuretic. "We are at the point of leaving behind an
era"]

Björn Dahlöf
MMW Fortschr Med - 2005-01-01
Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL
study

Björn Dahlöf, P. Gosse, P. Gueret, O. Dubourg, G. de Simone, R. Schmieder, Y. Karpov, J. Garcia-Puig, L. Matos, P. W. De Leeuw, J. P. Degaute, D. Magometschnigg
J Hypertens - 2005-01-01
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled
trial

Björn Dahlöf, P. S. Sever, N. R. Poulter, H. Wedel, D. G. Beevers, M. Caulfield, R. Collins, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren
Lancet - 2005-01-01
Introduction

Björn Dahlöf, E. Ritz
Acta Diabetol - 2005-01-01
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE
studies

A. A. Carr, P. R. Kowey, R. B. Devereux, B. M. Brenner, Björn Dahlöf, H. Ibsen, L. H. Lindholm, P. A. Lyle, S. M. Snapinn, Z. Zhang, J. M. Edelman, S. Shahinfar
Am J Cardiol - 2005-01-01
Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE
Study)

K. Boman, M. Olofsson, Björn Dahlöf, E. Gerdts, M. S. Nieminen, V. Papademetriou, K. Wachtell, R. B. Devereux
Am J Cardiol - 2005-01-01
Cost analysis of different pharmacological treatment strategies in elderly
hypertensives.

Erland Linjer, Thomas Hedner, Bengt Jönsson, Tord Ekbom, Lars H Lindholm, Björn Dahlöf, Ulf De Faire, Bengt Scherstén
Blood pressure - 2005-01-01
Diuretics in the LIFE study -
Reply

Johji Kato, Tanenao Eto, Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen
Lancet - 2004-01-01
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular
disease

S. Mochizuki, M. Shimizu, I. Taniguchi, K. Kanae, S. Yoshida, N. Tajima, Björn Dahlöf
Cardiovasc Drugs Ther - 2004-01-01
Surrogate markers for cardiovascular disease: structural
markers

G. B. Mancini, Björn Dahlöf, J. Diez
Circulation - 2004-01-01
Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE
study

Z. B. Li, K. Wachtell, P. M. Okin, E. Gerdts, J. E. Liu, M. S. Nieminen, Sverker Jern, Björn Dahlöf, R. B. Devereux
J Hum Hypertens - 2004-01-01
Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE
study

J. Kontos, V. Papademetriou, K. Wachtell, V. Palmieri, J. E. Liu, E. Gerdts, K. Boman, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
J Hum Hypertens - 2004-01-01
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE
study

S. Julius, M. H. Alderman, G. Beevers, Björn Dahlöf, R. B. Devereux, J. G. Douglas, J. M. Edelman, K. E. Harris, S. E. Kjeldsen, S. Nesbitt, O. S. Randall, J. T., Jr. Wright
J Am Coll Cardiol - 2004-01-01
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in
hypertension

K. A. Jamerson, G. L. Bakris, C. C. Wun, Björn Dahlöf, M. Lefkowitz, S. Manfreda, B. Pitt, E. J. Velazquez, M. A. Weber
Am J Hypertens - 2004-01-01
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE
Study

H. Ibsen, K. Wachtell, M. H. Olsen, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, Björn Dahlöf
Kidney Int Suppl - 2004-01-01
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE
substudy

H. Ibsen, K. Wachtell, M. H. Olsen, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, Björn Dahlöf, R. B. Devereux, U. de Faire, F. Fyhrquist, S. Julius, S. E. Kjeldsen, O. Lederballe-Pedersen, M. S. Nieminen, P. Omvik, S. Oparil, Y. Wan
J Hypertens - 2004-01-01
The impact of serum uric acid on cardiovascular outcomes in the LIFE
study

A. Hoieggen, M. H. Alderman, S. E. Kjeldsen, S. Julius, R. B. Devereux, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel, C. Chen, Björn Dahlöf
Kidney Int - 2004-01-01
[Protection from stroke, updates and
perspectives]

M. Giroud, Björn Dahlöf, K. Watchtell, C. Thuillez
Presse Med - 2004-01-01
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE
study)

E. Gerdts, M. J. Roman, V. Palmieri, K. Wachtell, G. Smith, M. S. Nieminen, Björn Dahlöf, R. B. Devereux
J Hum Hypertens - 2004-01-01
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
trial

R. B. Devereux, Björn Dahlöf, E. Gerdts, K. Boman, M. S. Nieminen, V. Papademetriou, J. Rokkedal, K. E. Harris, J. M. Edelman, K. Wachtell
Circulation - 2004-01-01
Prognostic significance of left ventricular mass change during treatment of
hypertension

R. B. Devereux, K. Wachtell, E. Gerdts, K. Boman, M. S. Nieminen, V. Papademetriou, J. Rokkedal, K. Harris, P. Aurup, Björn Dahlöf
Jama - 2004-01-01
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE)
study

Björn Dahlöf, T. A. Burke, K. Krobot, G. W. Carides, J. M. Edelman, R. B. Devereux, H. C. Diener
J Hum Hypertens - 2004-01-01
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized
trial

M. M. Ciulla, R. Paliotti, A. Esposito, J. Diez, B. Lopez, Björn Dahlöf, M. G. Nicholls, R. D. Smith, L. Gilles, F. Magrini, A. Zanchetti
Circulation - 2004-01-01
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE
study

J. N. Bella, V. Palmieri, K. Wachtell, J. E. Liu, E. Gerdts, M. S. Nieminen, M. J. Koren, M. Zabalgoitia, J. T. Wright, Björn Dahlöf, R. B. Devereux
J Hum Hypertens - 2004-01-01
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension
Study

L. Oikarinen, M. S. Nieminen, M. Viitasalo, L. Toivonen, Sverker Jern, Björn Dahlöf, R. B. Devereux, P. M. Okin
Hypertension - 2004-01-01
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular
events

P. M. Okin, R. B. Devereux, Sverker Jern, S. E. Kjeldsen, S. Julius, M. S. Nieminen, S. Snapinn, K. E. Harris, P. Aurup, J. M. Edelman, H. Wedel, L. H. Lindholm, Björn Dahlöf
Jama - 2004-01-01
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE
study

P. M. Okin, R. B. Devereux, J. E. Liu, L. Oikarinen, Sverker Jern, S. E. Kjeldsen, S. Julius, K. Wachtell, M. S. Nieminen, Björn Dahlöf
J Hum Hypertens - 2004-01-01
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive
patients

P. M. Okin, R. B. Devereux, M. S. Nieminen, Sverker Jern, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, S. Julius, S. Snapinn, Björn Dahlöf
Hypertension - 2004-01-01
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE
substudy)

M. H. Olsen, K. Wachtell, J. N. Bella, J. E. Liu, K. Boman, E. Gerdts, V. Papademetriou, M. S. Nieminen, J. Rokkedal, Björn Dahlöf, R. B. Devereux
Am J Cardiol - 2004-01-01
Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE
substudy

M. H. Olsen, K. Wachtell, J. N. Bella, V. Palmieri, E. Gerdts, G. Smith, M. S. Nieminen, Björn Dahlöf, H. Ibsen, R. B. Devereux
J Hum Hypertens - 2004-01-01
Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE
study

V. Palmieri, K. Wachtell, J. N. Bella, E. Gerdts, V. Papademetriou, M. S. Nieminen, Björn Dahlöf, M. J. Roman, R. B. Devereux
J Hum Hypertens - 2004-01-01
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE
study

H. M. Reims, S. E. Kjeldsen, W. E. Brady, Björn Dahlöf, R. B. Devereux, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel
J Hum Hypertens - 2004-01-01
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE
study

H. M. Reims, S. Oparil, S. E. Kjeldsen, R. B. Devereux, S. Julius, W. E. Brady, F. Fyhrquist, H. Ibsen, L. H. Lindholm, P. Omvik, H. Wedel, G. Beevers, U. de Faire, K. Kristianson, O. Lederballe-Pedersen, M. S. Nieminen, Björn Dahlöf
Blood Press - 2004-01-01
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled
trial

P. S. Sever, Björn Dahlöf, N. R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren
Drugs - 2004-01-01
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
study

K. Wachtell, V. Papademetriou, G. Smith, E. Gerdts, Björn Dahlöf, E. Engblom, G. P. Aurigemma, J. N. Bella, H. Ibsen, J. Rokkedal, R. B. Devereux
Am Heart J - 2004-01-01
Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in
STOP-Hypertension-2.

Tord Ekbom, Erland Linjer, Thomas Hedner, Jan Lanke, Ulf De Faire, P-O Wester, Björn Dahlöf, Bengt Scherstén
Blood pressure - 2004-01-01
Perceived symptoms amongst hypertensive patients in routine clinical practice- a population-based
study.

Karin I Kjellgren, Johan Ahlner, Björn Dahlöf, H Gill, Thomas Hedner, Roger Säljö
Journal of internal medicine - 1998-01-01
Patients' and physicians' assessment of risks associated with hypertension and benefits from
treatment.

Karin I Kjellgren, Johan Ahlner, Björn Dahlöf, R. H. Gill, Thomas Hedner, Roger Säljö
Journal of cardiovascular risk - 1998-01-01
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH
Group.

Sverker Jern, L Hansson, B Scherstén, S Kullman, S Sörensen, Björn Dahlöf, Robert Eggertsen, Ramon Eivertsson
Journal of cardiovascular pharmacology - 1991-01-01
Additive effect of isradipine in combination with captopril in hypertensive
patients.

Robert Eggertsen, A Svensson, Björn Dahlöf, L Hansson
The American journal of medicine - 1989-01-01
Calcium antagonists combined with beta-blockers or ACE inhibitors in the treatment of
hypertension.

Björn Dahlöf, Robert Eggertsen, Lennart Hansson
Journal of cardiovascular pharmacology - 1988-01-01
Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential
hypertension.

Björn Dahlöf, Lennart Andrén, Robert Eggertsen, Sverker Jern, Anders SVensson, A Sievert, Mattias Aurell, Lennart Hansson
Journal of cardiovascular pharmacology - 1987-01-01
The long-term effect of isradipine in pindolol-treated
patients.

Björn Dahlöf, Lennart Andrén, Robert Eggertsen, Sverker Jern, Anders SVensson, Lennart Hansson
Journal of hypertension. Supplement : official journal of the International Society of Hypertension - 1987-01-01
Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of
hydrochlorothiazide.

Björn Dahlöf, Lennart Andrén, Robert Eggertsen, Sverker Jern, Anders SVensson, Lennart Hansson
Journal of hypertension. Supplement : official journal of the International Society of Hypertension - 1985-01-01
[Review of new pharmacological treatment principles in
hypertension].

Lennart Andrén, Björn Dahlöf, Robert Eggertsen, T Gudbrandsson, Lennart Hansson, Sverker Jern, Ramon Sivertsson, Anders SVensson
Nordisk medicin - 1983-01-01
Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor
antagonist.

Lennart Andrén, Anders SVensson, Björn Dahlöf, Robert Eggertsen, Lennart Hansson
Acta medica Scandinavica - 1983-01-01
[A review of recent pharmacological therapeutic principles in
hypertension].

Lennart Andrén, Björn Dahlöf, Robert Eggertsen, T Gudbrandsson, Lennart Hansson, Sverker Jern, Ramon Sivertsson, Anders SVensson
Lakartidningen - 1983-01-01